Related Experiment Videos
[Bone marrow transplantation in leukemia and aplastic anemia]
Schweizerische Medizinische Wochenschrift
|April 30, 1983
Summary
Allogeneic bone marrow transplantation (BMT) significantly improves leukemia outcomes when using cyclophosphamide, total body irradiation, and cyclosporin-A for graft-versus-host disease prophylaxis. Early BMT for acute leukemia and chronic granulocytic leukemia shows promising survival rates.
Area of Science:
- Hematology
- Oncology
- Immunology
Context:
- Allogeneic bone marrow transplantation (BMT) is a critical treatment for leukemia and severe aplastic anemia (SAA).
- Optimizing conditioning regimens and graft-versus-host disease (GvHD) prophylaxis is essential for improving patient outcomes.
- Advances in immunosuppression and early intervention have transformed BMT efficacy.
Purpose:
- To analyze the outcomes of 50 leukemia BMT cases and 86 SAA cases treated between 1979 and 1982.
- To evaluate the effectiveness of cyclophosphamide (Cy) and total body irradiation (TBI) conditioning.
- To assess the impact of cyclosporin-A (CyA) for GvHD prophylaxis compared to methotrexate (MTX).
Summary:
- Cyclophosphamide (Cy) and total body irradiation (TBI) conditioning, early BMT for acute leukemia (AL) and chronic granulocytic leukemia (CGL), and cyclosporin-A (CyA) for GvHD prophylaxis are crucial for leukemia BMT.
- Survival rates for AL in first remission and CGL in chronic phase were high (7/13 AML, 8/9 ALL, 7/10 CGL).
- Cyclosporin-A (CyA) significantly reduced severe GvHD and interstitial pneumonia compared to methotrexate (MTX), though it was insufficient for HLA-haploidentical transplants.
- For severe aplastic anemia (SAA), antilymphocyte globulin (ALG) and high-dose prednisone achieved 90% remission rates, crucial for patients lacking HLA-identical siblings.
Impact:
- Cyclosporin-A (CyA) has drastically reduced GvHD incidence and severity in allogeneic BMT for leukemia.
- Improved conditioning and prophylaxis strategies have increased BMT success rates, particularly for patients with SAA.
- These findings underscore the importance of tailored immunosuppression and transplant timing for optimizing BMT outcomes in hematologic malignancies and bone marrow failure syndromes.